Fluoride: Page 54

FDA OKs new drug to treat thyroid cancer
By DrBicuspid.com staff writers
The U.S. Food and Drug Administration (FDA) has approved vandetanib to treat adult patients with late-stage medullary thyroid cancer who are ineligible for surgery and whose disease is growing or causing symptoms.
April 6, 2011
NIH awards $2M grant for oral mucositis treatment
By DrBicuspid.com staff writers
Biotech firm Synedgen has been awarded a $1.96 million phase II Small Business Innovation Research grant by the National Institutes of Health (NIH) to accelerate the development of Synedgen's proprietary oral disease treatments.
March 22, 2011
Septodont acquires OraVerse from Novalar
By Kathy Kincade
Septodont has acquired the OraVerse product line from Novalar Pharmaceuticals, the companies announced today. OraVerse is the first local anesthesia reversal agent to gain U.S. Food and Drug Administration approval.
March 17, 2011
2009 03 06 12 05 35 84 Fear Needle
Perio drug reduces risk of osteoporosis, heart disease
By DrBicuspid.com staff writers
A drug approved by the U.S. Food and Drug Administration (FDA) for treating periodontal disease could also significantly reduce the risk of osteoporosis and cardiovascular disease in postmenopausal women, according to a study in the Journal of the American Dental Association.
March 10, 2011
Epileptic drug can cause oral birth defects
By DrBicuspid.com staff writers
New data suggest that the drug Topamax (topiramate) and its generic versions increase the risk for cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration is warning.
March 3, 2011
Merck wins latest Fosamax/ONJ lawsuit
By DrBicuspid.com staff writers
A state court in New Jersey has found in favor of Merck in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw-related problems on her Fosamax use.
February 13, 2011
Tenn. legalizes Botox use for oral surgeons
By Rabia Mughal
The Tennessee dental board has approved the use of Botox injections by oral and maxillofacial surgeons and considerations are under way that might allow general dentists to use the drug in the future.
February 3, 2011
2010 05 06 09 46 14 716 Botox 70
Amgen to pay $1B for firm developing head/neck cancer drug
By DrBicuspid.com staff writers
Biotechnology giant Amgen has agreed to acquire BioVex Group, a privately held biotechnology company that is developing OncoVex, a novel oncolytic vaccine to treat head and neck cancer and melanoma.
January 23, 2011
FDA warns Dentsply about advertising violations
By Rob Goszkowski
In what is being characterized as "serious" violations, the U.S. Food and Drug Administration has issued a warning letter to Dentsply for misbranding its localized anesthetic Oraqix in a journal ad and professional mailers.
January 18, 2011
2009 07 28 13 33 39 581 Fda Logo 70
4th Merck osteonecrosis trial begins
By DrBicuspid.com staff writers
Merck will again "vigorously defend itself" against allegations that its Fosamax bisphosphonate drug caused dental and jaw-related problems in a jury trial that began January 18 in New Jersey.
January 17, 2011
FDA limits acetaminophen in combination products
By DrBicuspid.com staff writers
The U.S. Food and Drug Administration (FDA) is asking manufacturers of prescription combination products that contain acetaminophen to limit the amount of acetaminophen to no more than 325 milligrams in each tablet or capsule.
January 12, 2011
Moxifloxacin beats clindamycin for some odontogenic infections
By Reuters Health
NEW YORK (Reuters Health) - Moxifloxacin was significantly more effective than clindamycin at controlling the pain of odontogenic/gingival inflammatory infiltrates, in a small phase II study by German researchers.
January 9, 2011
2009 07 13 09 44 04 276 Bottle Pills 70
Previous Page
Page 54 of 62
Next Page